

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INITERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

51) International Patent Classification ⁶ : C07J 41/00, A61K 31/57, C07J 43/00, A61K 31/56, 31/575, 31/58	A3	(11) International Publication Number: (43) International Publication Date:	WO 99/33859 8 July 1999 (08.07.99)
	US]; 3: JS). Alto, Copark Circ 510 Oric Ling; 6	BY, CA, CH, CN, CU, CZ, DE, GH, GM, HR, HU, ID, IL, IN, KZ, LC, LK, LR, LS, LT, LU, MW, MX, NO, NZ, PL, PT, RO SL, TJ, TM, TR, TT, UA, UG, patent (GH, GM, KE, LS, MW, S patent (AM, AZ, BY, KG, KZ, N patent (AT, BE, CH, CY, DE, IE, IT, LU, MC, NL, PT, SE), CG, CI, CM, GA, GN, GW, MI Published With international search report. (88) Date of publication of the international search report.	DK, EE, ES, FI, GB, GE, IS, IP, KE, KG, KP, KR, LV, MD, MG, MK, MN, RU, SD, SE, SG, SI, SK, UZ, VN, YU, ZW, ARIPO DD, SZ, UG, ZW), Eurasiar ID, RU, TJ, TM), Europear DK, ES, FI, FR, GB, GR OAPI patent (BF, BJ, CF, MR, NE, SN, TD, TG).

(57) Abstract

Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependant disorders. Preferred compounds have 1,3,5-estratiene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratienes. Therapeutic methods and pharmaceutical compositions are provided as well.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	īL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		2
DE	Germany	LI	Liechtenstein	SD	Sudan		
	Denmark	LK	Sri Lanka	SE	Sweden		
DK		LR	Liberia	SG	Singapore		
EE	Estonia	LR	Liocia	50	~O-T		

PCT/US 98/27406

		PCT/US 98/	2/406
A. CLASSII IPC 6	FICATION OF SUBJECT MATTER C07J41/00 A61K31/57 C07J43/ A61K31/58	'00 A61K31/56 A61K3	1/575
According to	o International Patent Classification (IPC) or to both national classif	ication and IPC	
	SEARCHED		
Minimum do IPC 6	ocumentation searched (classification system followed by classification ${\tt C07J-A61K}$	ation symbols)	
Documenta	tion searched other than minimum documentation to the extent tha	t such documents are included in the fields sea	arched
Electronic d	tata base consulted during the international search (name of data i	pase and, where practical, search terms used)	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
Α	POIRIER D ET AL: "D-ring alkylderivatives of estradiol: effect ER-binding affinity and antiest	t on	8-11, 14-20, 23-36,41
	activity" BIOORGANIC & MEDICINAL CHEMISTR vol. 6, no. 21, 5 November 1996 (1996-11-05), p 2537-2542 XP004135909 the whole document		
A	PETERS R H ET AL: "17-DESOXY E ANALOGUES" JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 7, July 1989 (1989 1642-1652, XP002005625 page 1646; tables II, III in par	-07), pages	8-10, 14-19, 23-37
	table II, compounds 12,24,36 on	page 1646	
X Fun	ther documents are listed in the continuation of box C.	X Patent family members are listed	in annex.
"A" docum consider "E" earlier filing "L" docum which citatio "O" docum other	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or means	"T" later document published after the inter or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an inventive step when the document is combined with one or moments, such combined with one or moments, such combination being obvious in the art.	the application but laimed invention be considered to current is taken alone laimed invention rentive step when the re other such docu-
	nent published prior to the international filing date but than the priority date claimed	"&" document member of the same patent	amily
	e actual completion of the international search 26 July 1999	Date of mailing of the international see	
	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Watchorn, P	

8

PCT/US 98/27406

8-10, 14-16, 23-36,41 8-10, 14-16, 23-36,41 8-10, 14-19,
8-10, 14-16, 23-36,41 8-10, 14-16, 23-36,41
8-10, 14-16, 23-36,41 8-10, 14-19,
14-16, 23-36,41 8-10, 14-19,
8-10, 14-19,
14-19,
23-36,41
25 50,41
8-10, 14-19, 23-36,41
20 00,41
14
8,14,41
14
8,14

8,14, 23-36,41
8,14
8,14,
8,14,
8,14, 28-30, 33,35, 36,41
8-10, 17-19, 23-36,41
8-10, 17-19, 23-36,41
8-10, 17-19, 23-36,41

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 405 147 A (COUNSELL RAYMOND E ET AL) 8 October 1968 (1968-10-08)	20,28, 30,31, 33,35, 36,41
	column 2, line 24 - line 31; examples 7-9	33,12
A	STRECKE, J. ET AL: "Animal experiments on the estrogenic and antiestrogenic effects of	11, 23-25, 30-36,41
	17.alphathiocyanomethyl-17.betatetrahy dropyranyloxyestra- 1,3,5(10)-triene-3-methylether and 17.beta	
	phenylaminocarbonyloestra-1,3,5(10)-triene -3-methylether" PHARMAZIE,	
	vol. 32, no. 10, October 1997 (1997-10), pages 598-602, XP002109817 BERLIN DE compound 1 on page 598, column 1	
Α	WO 96 03995 A (HOLICK MICHAEL F) 15 February 1996 (1996-02-15)	11-13, 20, 23-36,41
	page 5, line 1 - line 6; claim 9	23 33,41
A	CHEMICAL ABSTRACTS, vol. 76, no. 21, 22 May 1972 (1972-05-22) Columbus, Ohio, US; abstract no. 122090, AGRESTA, G. ET AL: "Biological activities of a new acetalic ether of estradiol, 17.beta(1',4'-dioxan-2'-yloxy)-estra-1,3,5(10)-trien-3-ol (17-dioxanylestradiol)" page 83; column 1; XP002109825 abstract & ACTA ENDOCRINOL. (COPENHAGEN) (1972), 69(1), 95-106,	11-13, 20,23-36
A	H BRUNNER ET AL: "Synthese und Antitumoraktivität von cis-Dichloroplatin(II) -Komplexen mit Östradiolderivaten" MONATSHEFTE FUR CHEMIE, vol. 124, no. 1,	11-13, 20, 23-36,41
C	1 January 1993 (1993-01-01), pages 83-102, XP002089839 ISSN: 0026-9247 page 98, compounds 13,14; page 90, paragraph 4; page 91; table 2; page 92, paragraph 3 - page 93, paragraph 1	
-	-/	

Category °	inition) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ategory *	Chance of document, were removed to the relevant passages	i iolovana to olaim ino.
(US 3 431 258 A (LEFEBVRE YVON ET AL) 4 March 1969 (1969-03-04) example 2	11,20
	US 3 271 392 A (Y. LEFEBVRE) 6 September 1966 (1966-09-06) the whole document, in particular column 1, lines 34-50	11-13, 23-36,41
	BE 661 288 A (ROUSSEL-UCLAF) 20 September 1965 (1965-09-20) page 3, paragraph 2 - paragraph 4; example 1	11,20, 30,41
4	EL GARROUJ, DRISS ET AL: "Steroidal Affinity Labels of the Estrogen Receptor 2.17 alpha-'(Haloacetamido)alkyl! estradiols" JOURNAL OF MEDICINAL CHEMISTRY., vol. 38, no. 13, 23 June 1995 (1995-06-23), pages 2339-2348, XP002109818 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 page 2341, compounds 19,21,23 page 2341, column 2, paragraph 2 page 2342; table 1	11,20, 23-36,41
:	ALIAU, SIGRID ET AL: "17.alpha(Haloacetamidoalkyl)estradiols alkylate the human estrogen receptor at cysteine residues 417 and 530" BIOCHEMISTRY., vol. 36, no. 19, 13 May 1997 (1997-05-13), pages 5861-5867, XP002109819 AMERICAN CHEMICAL SOCIETY. EASTON, PA., US ISSN: 0006-2960 page 5862, column 1, compounds 2B, 3B, 3I and figure 1 page 5864, column 2, paragraph 2	11,20, 23-36,41
A	US 3 946 052 A (CROWE DAVID F ET AL) 23 March 1976 (1976-03-23) the whole document	11,20, 23-36,41
A	F. KINCL: "Notiz über den Mechanismus der Anti-Ovulation mit 6-Chloro-delta-6-17.alphaAcetoxyprogeste ron in Kaninchen" ENDOKRINOLOGIE, vol. 44, no. 1/2, 1963, pages 67-71, XP002109820 LEIPZIG, DE the whole document, in particular page 69;	37

C /C-=	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/05 98/2/400
Category °		Relevant to claim No.
A	F. KINCL ET AL: "Antifertility Activity of Various Steroids in the Female Rat" JOURNAL OF REPRODUCTION AND FERTILITY, vol. 10, 1965, pages 105-113, XP002109821 OXFORD, GB page 108; table 3	37
A	US 3 766 171 A (MARX A ET AL) 16 October 1973 (1973-10-16) column 2, line 15 - line 21; example 15	38
A	CHEMICAL ABSTRACTS, vol. 114, no. 10, 11 March 1991 (1991-03-11) Columbus, Ohio, US; abstract no. 88501, BASU, KRISHNAKALI ET AL: "Effects of 3-hydrazone modification on the metabolism and protein binding of progesterone" page 429; column 2; XP002109826 abstract & INT. J. PHARM. (1990), 65(1-2), 109-14,	38
A	WO 97 22618 A (VERTEX PHARMA) 26 June 1997 (1997-06-26) page 30, paragraph 1	38
X Y	US 5 554 603 A (KIM HYUN K ET AL) 10 September 1996 (1996-09-10) column 15, line 16 - line 19; figure 4	3 9 39
X Y	WO 87 00175 A (STANFORD RES INST INT) 15 January 1987 (1987-01-15) page 28, line 15 - line 21; examples 1-9 page 31, line 12 - line 18	39
	page 32, line 22 - page 33, line 10	
Y	PETERS, RICHARD H. ET AL: "11.betaNitrate estrane analogs: potent estrogens" JOURNAL OF MEDICINAL CHEMISTRY., vol. 32, no. 10, October 1989 (1989-10), pages 2306-2310, XP002109822 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 the whole document	39
Ρ,Χ	WO 98 07740 A (SCHERING AG) 26 February 1998 (1998-02-26) page 15, paragraph 2; example 30	39
Y	US 3 318 925 A (G. ANNER ET AL) 9 May 1967 (1967-05-09) example 1	40
	-/	

.(Continu	Ition) DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory °	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
	N. PEMMARAJU ET AL: "Preparative chemical methods for aromatisation of 19-nor-delta-4,-3-oxosteroids" STEROIDS., vol. 59, no. 11, November 1994 (1994-11), pages 621-627, XP002109823 ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY., US page 624; table 2	40
Y	SUN-SHINE YUAN: "Synthesis of 3,4-13C2 Steroids" STEROIDS., vol. 39, no. 3, March 1982 (1982-03), pages 279-289, XP002109824 ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY., US page 288, paragraph 2	40
Y	US 3 859 365 A (YOUNG DAVID A) 7 January 1975 (1975-01-07) the whole document	40

...ernational application No.

PCT/US 98/27406

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim(s) 23-39 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: 1-7 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See further information sheet
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see further information sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.
Life process accompanied the payment of additional road of the payment of

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-7

Claims 1-7 attempt to define the subject matter of the claimed invention in terms of a result to be achieved, claims 1-3 in particular give no structural features of the claimed compounds AT ALL, but rather define them in terms of their anti-estrogenic effects and low estrogenic activity. Claims 4-7 further specify two very trivial structural features, namely the estra-1,3,5(10)-triene structure and the 17-desoxy derivative thereof. These per se are well known structural features and give no distinction of the claimed subject matter over the state of the art, consequently the (allegedly) distinguishing feature of each of these claims is their function as anti-estrogens with low estrogenic activity as measured by a well known technique. This is also the problem to be solved by the claimed compounds (see page 5, lines 10-13 of the description). Consequently the subject matter of claims 1-7 is entirely characterised by a desideratum, i.e. the distinguishing feature of these claims over the prior art is simply to state that they must be of such a structure that they solve the stated problem. This is a wholly unacceptable formulation from the point of view of the clarity of the claims according to Article 6 PCT, since the skilled person is given no hint whatsoever in these claims as to the technical means needed to solve the stated problem and also, for the same reason, from the standpoint of sufficiency of disclosure of these claims (Article 5 PCT), since the skilled person is at a loss as to which compounds to synthesise with any expectation of solving the problem. Consequently these claims are so unclear under Article 6 PCT and insufficiently disclosed (Article 5 PCT), that it is not possible to carry out a meaningfull search thereon according to Article 17(2)(a)(ii) and (2)(b) PCT. Consequently these claims are not mentioned anywhere in the search report or in the non-unity motivation.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 8-10,14,23-36,41 (in part) 15,16 (in full)

Estra-1,3,5(10)-triene compounds with a cyclic substituent bound, optionally via a linker group, to position 17 of the steroid skeleton via a doubly bonded carbon or nitrogen atom, medical uses and pharmaceutical compositions thereof.

2. Claims: 8,14,23-36,41 (in part)

Estra-1,3,5(10)-triene compounds with a linear hydrocarbon substituent interrupted by at least one -0-, -S- or -NR-moiety and bound, optionally via a linker group, to position 17 of the steroid skeleton via a doubly bonded carbon or nitrogen atom, medical uses and pharmaceutical compositions thereof.

3. Claims: 8-10,23-36,41 (in part) 17-19 (in full)

Estra-1,3,5(10)-triene compounds substituted in position 11 by a doubly bound carbon or nitrogen atom, medical uses and pharmaceutical compositions thereof.

4. Claims: 11,20,23-36,41 (in part) 12,13,21,22 (in full)

17-Desoxy-estra-1,3,5(10)-triene compounds with a cyclic substituent bound, optionally via a linker group, to position 17 of the steroid skeleton via a singly bonded carbon atom, medical uses and pharmaceutical compositions thereof.

5. Claims: 11,20,23-36,41 (in part)

17-Desoxy-estra-1,3,5(10)-triene compounds with a linear hydrocarbon substitutent, interrupted by at least one -0-, -S-, or -NR- moiety, bound to position 17 of the steroid skeleton via a singly bonded carbon atom, medical uses and pharmaceutical compositions thereof.

6. Claims: 37,38 (in full)

The treatment of estrogen dependent disorders using pregna-1,3,5(10)-trien-3-ol-20-one or the hydrazone thereof

7. Claim: 39 (in full)

A method for transdermal delivery of estra-1,3,5(10)-triene

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

steroids.

8. Claim: 40 (in full)

A process for the production of 7.alpha.-methyl-estrone.

Information on patent family members

PCT/US 98/27406

I in search report		date		nember(s)	
3318917	Α.	09-05-1967	GB	1134766 A	date
3448120 		03-06-1969 	NONE	~~~~~~	
9313123	Α	08-07-1993	FR	2685332 A	25-06-1993
					15-05-1998 29-02-1996
					28-07-1993
			CA	2124339 A	08-07-1993
			CN		
					28-05-1998 29-10-1998
					09-11-1994
			ËS		01-07-1998
			FΙ	942944 A	17-06-1994
		•			29-05-1995
					13-07-1997
					09-03-1995 01-07-1993
			NZ	246624 A	21-12-1995
			ZA	9209859 A	20-12-1993
3271428	Α	06-09-1966	DE	1493150 A	07-08-1969
				4691 M	
					20 10 100
					29-12-1964 06-09-1966
			JP	48013111 B	25-04-1973
3536703	A	27-10-1970	GB	1255840 A	01-12-1971
3716530	Α	13-02-1973	AR	195561 A	23-10-1973
					10-01-1974
					09-02-1973 22-02-1973
					30-03-1973
			GB	1365205 A	29-08-1974
				48028462 A	14-04-1973
					13-02-1973 25-04-1973
2012				7204354 A	25-04-1973
		10.01.1054			
		19-01-1954		~	
	~~~				
2840581	Α	24-06-1958 	NONE		
2361120	Α	12-06-1974	NL NL	7216767 A	11-06-1974
,					20-05-1975 25-05-1982
			AT		15-10-1981
			AU	6326373 A	05-06-1975
			BE	808391 A	07-06-1974
		4			22-11-1977
			DK	293776 A	30-11-1979 B, 30-06-1976
	3271428 3536703 3716530 3012 2666769 43021058 2840581	9313123 A  3271428 A  3536703 A  3716530 A  3012 M  2666769 A  43021058 B  2840581 A	9313123 A 08-07-1993  3271428 A 06-09-1966  3536703 A 27-10-1970  3716530 A 13-02-1973  3012 M 2666769 A 19-01-1954  43021058 B 2840581 A 24-06-1958	9313123 A 08-07-1993 FR AT AU AU CA CN DE DE EP ES FI HU IL JP MX NZ ZA S3271428 A 06-09-1966 DE FR GB NL US JP S3536703 A 27-10-1970 GB S716530 A 13-02-1973 AR AU BE DE FR GB JP NL ZA S012 M NONE 2666769 A 19-01-1954 NONE 43021058 B NONE 2840581 A 24-06-1958 NONE 2361120 A 12-06-1974 NL NL AT AT AU BE CCA CH	9313123 A 08-07-1993 FR 2685332 A AT 165365 T AU 666916 B AU 3357093 A CA 2124339 A CA 2124329 A CA 2209259 A CA 2209259 A CA 2209859 A

Information on patent family members

Patent document cited in search report		Publication date		atent family member(s)	Publication date
DE 2361120	Α	<del></del>	DK	135047 B	28-02-1977
	- •		FI	54128 B	30-06-1978
			FR	2209577 A	05-07-1974
			GB	1455270 A	10-11-1976
		•	IE	38617 B	26-04-1978
			JP	1289124 C	14-11-198
					25-03-197
			JP	50029548 A	
			JP	59033600 B	16-08-1984
			PH	11191 A	28-10-1977
			SE	414771 B	18-08-1980
			US	3927046 A	16-12-197!
			ZA	7309161 A	30-10-197
EP 0471612	Α	19-02-1992	FR	2665901 A	21-02-199
			AT	162797 T	15-02-1998
			AU	8242291 A	20-02-199
			CA	2049102 A	15-02-199
			DE	69128820 D	05-03-199
			DE	69128820 T	10-06-199
			ES	2112268 T	01-04-199
			GR	3026315 T	30-06-199
			JP	6340688 A	13-12-199
			PT		31-07-199
				98681 A,B	
			US	5707982 A	13-01-199
EP 0546591	Α	16-06-1993	DE	4132182 A	25-03-199
			ĀŤ	146185 T	15-12-199
			CA	2119780 A	01-04-199
			DE	59207687 D	23-01-199
			DK	642529 T	02-06-199
			MO	9306124 A	01-04-199
			WO EP		15-03-199
				0642529 A	16-04-199
			ES	2097924 T	
			GR	3022692 T	31-05-199
			JP	7501792 T	23-02-199
			US	5502046 A	26-03 <b>-199</b>
US 3405147	A	08-10-1968	NONE		
WO 9603995	Α	15-02-1996	US	5612317 A	18-03-199
•			CA	2226140 A	15-02-199
			EP	0894000 A	03-02-199
US 3431258	Α	04-03-1969	CH	561739 A	15-05-197
			DE	1618065 A	25-03-197
			FR	7151 M	04-08-196
			FR	1534765 A	
			GB	1190403 A	06-05-197
			NL	6707219 A	27-11-196
			ÜS	3398138 A	20-08-196
IIC 3271202	Λ	06-00-1066	 CH	463500 A	
US 3271392	А	00-03-1300			DE_00 107
			DE	1568013 A	05-02-197
			FR	6863 M	14-04-196
			FR	1484102 A	13-09-196
			GB NL	1145336 A 6607840 A	15-03-196

Information on patent family members

Pa	tent document		Publication		atent family	Publication
cited in search report			date		member(s)	date
BE	661288	Α	20-09-1965	СН	435266 A	
				DE	1468902 A	23-04-1970
				DK	115110 B	08-09-1969
			-	FR	3851 M	00 00/2000
				FR	1512326 A	23-04-1968
						25.041300
				GB	1066301 A	
				GB	1066302 A	
				GB	1066303 A	
				NL	6503558 A	28-09-1965
				SE	320966 B	23-02-1970
				US	3291690 A	13-12-1966
US	3946052	Α	23-03-1976	NONE	,	
LIS	3766171	Α	16-10-1973	AT	316021 B	15-05-1974
-	3,001/1	13	10 10 15/3	BE	763895 A	06-09-1971
				CA	943537 A	12-03-1974
				DE	2110523 A	16-09-1971
				DK	125643 B	19-03-1973
				FR	208 <b>5681</b> A	31-12-1 <b>971</b>
				GB	1305752 A	07-02-1973
				IE	35257 B	24-12-1975
				NL	7103014 A	08-09-1971
				SE	380027 B	27-10-1975
				ZA	7101431 A	28-06-1972
MU 	9722618		26-06-1997	US	E9/300/ A	01-12-1998
,,,	3,22010	А	20 00 1331	AU	5843904 A 1465897 A	14-07-1997
				CA	2240489 A	26-06-1997
				CN	1207743 A	10-02-1999
				CZ	9801905 A	11-11-1998
				EP	0876395 A	11-11-1998
			•	NO	982774 A	19-08-1998
				PL	327333 A	07-12-1998
US	5554603	 A	10-09-1996	AT	160573 T	15-12-1997
			<b></b>	AU	700576 B	07-01-1999
				AU.	7728494 A	03-04-1995
				DE	69407057 D	08-01-1998
			,			
				DE	69407057 T	09-04-1998
			•	EP	0719276 A	03-07-1996
				ES	2110258 T	01-02-1998
				GR	3025872 T	30-04-1998
				JP	9505802 T	10-06-1997
				WO	9507925 A	23-03-1995
WO	8700175		15-01-1987	US	4705783 A	10-11-1987
	<del>-</del>			AT	68001 T	15-10-1991
				DE	3681786 A	07-11-1991
				DK	98087 A	25-02-1987
				EP	0227813 A	08-07-1987
				FI	870808 A,B,	25-02-1987
				JP	8016117 B	21-02-1996
				JP	63500101 T	14-01-1988
				US	4859370 A	22-08-1989
				US	RE34136 E	01-12-1992
						~~~~~~~~

Information on patent family members

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO 98	307740	A		AU	4552097	A	06-03-1998
				EP	0920441		09-06-1999
				NO	990793		20-04-1999
				ÜS	5866560		02-02-1999
US 33	318925	A	09-05-1967	BE	673226	 A	02-06-1966
				CH	484084		15-01-1970
				DE	1244777	В	
				DΕ	1443681	Α	13-11-1969
				DE	1443682	Α	13-11-1969
				DE	1443683	Α	27-11-1969
				DE	1443684	Α	13-11-1969
				FR	6478	M	25-11-1968
				FR	6479	M	25-11-1968
				FR	648 0		25-11-1968
				FR	1418540		11-02-1966
				FR	1434172		17-06-1966
				FR		Α	17-06-1966
				FR		Α	17-06-1966
				FR		A	17-06-1966
				GB		A	
				GB	1087317		
				GB		A	
				GB	1087319		
				GB	1087320		
				NL	125069		
				NL	125071		25 06 1065
				NL		A	25-06-1965
				NL		A	25-06-1965
				NL NL	6415017		25-06-1965 25-06-1965
				NL NL		A	25-06-1965
				SE		A B	24-05-1971
				SE		В	24-05-1971
				SE	335528		01-06-1971
				SE	325026		22-06-1970
				SE		В	08-06-1970
				SE		В	08-06-1970
				SE	316769		03-11-1969
				US	3318926		09-05-1967
				US	3318927		09-05-1967
				US	3318928		09-05-1967
				US	3318929		09-05-1967
	 359365	———— А	07-01-1975	NONE			